TPF Benefits in Laryngeal and Hypopharyngeal Cancer

Introduction to TPF Benefits

The American Society of Clinical Oncology recommends TPF (docetaxel, cisplatin, 5-fluorouracil) as an induction regimen for organ preservation in laryngeal and hypopharyngeal cancers, achieving superior larynx preservation rates compared to cisplatin/5-FU alone, though it does not improve overall survival 1, 2

The GORTEC 2000-01 trial directly compared TPF versus PF induction in 213 patients with operable stage III/IV laryngeal or hypopharyngeal cancer requiring total laryngectomy, demonstrating the efficacy of TPF 3
The TAX323 and TAX324 trials specifically enrolled patients with laryngeal and hypopharyngeal squamous cell carcinomas, showing the benefits of TPF in these populations 1, 2

The European Organisation for Research and Treatment of Cancer (EORTC) recommends TPF induction chemotherapy for organ preservation in advanced larynx and hypopharynx cancer in patients who would otherwise require total laryngectomy 4, 5
Response to induction chemotherapy serves as a predictive biomarker for successful organ preservation, with complete response rates to induction correlating with T stage: 82% for T2, 48% for T3, and 0% for T4 tumors 2, 6

Eligible patients must meet specific criteria, including stage III/IV laryngeal or hypopharyngeal cancer requiring total laryngectomy, intermediate to advanced stage disease, adequate performance status, and a priority on larynx preservation 1, 2, 4, 7
The standard dosing for TPF induction regimen consists of docetaxel 75 mg/m², cisplatin 75-100 mg/m², and 5-fluorouracil 750-1000 mg/m²/day, administered every 3 weeks for 3 cycles 4

TPF carries substantial toxicity, including grade 3-4 neutropenia (35%), grade 3-4 leukopenia (27%), febrile neutropenia, grade 2 alopecia, and diarrhea (8% grade 3-4) 4
High dropout rates of 24% occur before completion of sequential therapy due to cumulative toxicity, with treatment-related mortality reaching 9.5% in some series 4, 5

Despite improved larynx preservation, TPF induction has critical limitations, including no improvement in overall survival compared to PF or concurrent chemoradiation, and overall survival remains poor at 15-22% at 5 years for hypopharyngeal cancer 1, 2, 4
Concurrent cisplatin-based chemoradiation offers superior locoregional control and is the preferred standard of care, with 5-year larynx preservation of 84% with concurrent chemoradiation versus 71% with induction PF followed by RT 1, 2, 4